Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 8/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799237 | 0.86 | TDP1 (0.48) | TDP1ALDH1A1TSHRMAPK1VCAM1 | |
| SCHEMBL11003986 | 0.86 | TDP1 (0.48) | TDP1ALDH1A1TSHRMAPK1VCAM1 | |
| SCHEMBL15845450 | 0.80 | ALDH1A1 (0.43) | TDP1ALDH1A1 | |
| SCHEMBL6362482 | 0.79 | ALDH1A1 (0.47) | TDP1ALDH1A1TSHRMAPK1VCAM1 | |
| SCHEMBL3928266 | 0.79 | ALDH1A1 (0.47) | TDP1ALDH1A1TSHRMAPK1CTSB | |
| SCHEMBL8959348 | 0.76 | ALDH1A1 (0.45) | TDP1ALDH1A1TSHRMAPK1CTSB | |
| SCHEMBL930320 | 0.75 | ALDH1A1 (0.46) | TDP1ALDH1A1HSD17B10 | |
| SCHEMBL6537811 | 0.75 | TDP1 (0.44) | TDP1ALDH1A1TSHRMAPK1VCAM1 | |
| SCHEMBL2599781 | 0.74 | AHR (0.48) | AHR | |
| SCHEMBL15845436 | 0.73 | ALDH1A1 (0.43) | TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101506158-A | Novel 6-5 series bicyclic heterocyclic derivative and medical application thereof | SANWA KAGAKU KENKYUSHO CO (JP) | 2009-08-12 | — | — | CN | disclosed |
| US-20090176841-A1 | NOVEL 6-5 SYSTEM BICYCLIC HETEROCYCLIC DERIVATIVE AND ITS PHARMACEUTICAL UTILITY | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-2036887-A1 | NOVEL 6-5 BICYCIC HETEROCYCLIC DERIVATIVE AND MEDICAL USE THEREOF | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176841-A1 | NOVEL 6-5 SYSTEM BICYCLIC HETEROCYCLIC DERIVATIVE AND ITS PHARMACEUTICAL UTILITY | TSHR, TRHR, THRA | TDP1 4717/4885ALDH1A1 2560/4885TSHR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.